<!doctype html><html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width,initial-scale=1"><meta name="x-apple-disable-message-reformatting"><!--[if !mso]><!--><meta http-equiv="X-UA-Compatible" content="IE=edge"><!--<![endif]--><title></title><!--[if mso]> <style type="text/css"> table { border-collapse: collapse; border: 0; border-spacing: 0; margin: 0; } div, td { padding: 0; } div { margin: 0 !important; } ul, li { margin: 0; } </style> <noscript> <xml> <o:OfficeDocumentSettings> <o:AllowPNG/> <o:PixelsPerInch>96</o:PixelsPerInch> </o:OfficeDocumentSettings> </xml> </noscript> <![endif]--><style>@media screen and (max-width: 460px) { .stb-two-col .stb-column { max-width: 100% !important; } } @media screen and (min-width: 461px) { .stb-two-col .stb-column { max-width: 50% !important; } } @media screen and (max-width: 640px) { img.stb-justify { width: 100% !important; } } .stb-one-col p, .stb-two-col p { margin: 0px !important; }</style></head><body class="$stb-htmlv3$"><div role="article" aria-roledescription="email" style="-webkit-text-size-adjust: 100%;-ms-text-size-adjust: 100%;padding: 20px 0px;margin: 0 auto;"><div style="height:0px;max-height:0px;border-width:0px;border: 0px;border-color:initial;border-image:initial;visibility:hidden;line-height:0px;font-size:0px;overflow:hidden;display:none;"></div><table id="$beacon$"><tbody><tr><td></td></tr></tbody></table><table id="stb-container" role="presentation" style="width:100%;" border="0" bordercolor=""><tbody><tr><td align="center"><!--[if mso]> <table role="presentation" align="center" style="width:630px;background:#ffffff;"> <tr> <td> <div class="outer"> <![endif]--><!--[if !mso]><!--><div class="outer" style="width:100%;max-width:630px;background:#ffffff;margin: 0px auto;"><!--<![endif]--><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td class="stb-text-box" style="padding:0 0;text-align:left;margin:0px;line-height:1.7;word-break:break-word;font-size:12px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#747579;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%" class="stb-permalink"><tbody><tr><td style="padding:15px 15px 0px 15px;"><div><span style="font-weight: bold; font-style: italic;" class="stb-bold stb-italic">2025-10-24</span></div></td></tr></tbody></table></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:0px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="text-align:center;font-size:0;box-sizing:border-box;"><a href="https://www.brpinsight.com/brand/11290" target="_blank" style="text-decoration: none; color: #0000ff;"><img src="https://img2.stibee.com/440332_2907895_1753165422184361025.png" alt="" style="width:476px;display:inline;vertical-align:bottom;text-align:center;max-width:100% !important;height:auto;border:0;" width="476" class="stb-center"></a></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;padding:0px 15px 0px 15px;"><div style="text-align: center;"><h2 class="main-visual--title" style="padding: 0px; margin: 0px; line-height: 1.7;"><span style="font-size: 16px;">제약 산업의 주요 뉴스를 고르고, </span><span style="font-size: 16px;">데이터를 더해 뉴스레터를 발행합니다. </span></h2></div></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;background:#000000;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;padding:5px 15px 5px 15px;"><h1 class="heading" style="padding: 0px; margin: 0px; line-height: 1.7;"><span class="stb-fore-colored" style="font-size: 16px; color: #ffffff;"><a href="https://www.kpanews.co.kr/article/show.asp?idx=264314&category=D" class="stb-fore-colored" style="color: #ffffff; text-decoration: none;" target="_blank"><span class="stb-bold" style="font-weight: bold;"><span>1200억 자디앙 제네릭 시대 '개막' 오리지널 교체 여부 관심</span>🔗</span></a></span></h1></td></tr></tbody></table><!--[if !mso]><!--><div class="stb-two-col" style="border:0;font-size:0;" name="base2column"><!--<![endif]--><!--[if mso]> <div class='stb-two-col' style='text-align:center;' > <![endif]--><!--[if mso]> <table role='presentation' width='100%' cellpadding='0' cellspacing='0' style='border:0;'> <tr> <![endif]--><!--[if mso]> <td style='width:50%;padding:15px 15px 0px 15px;' valign='top'> <![endif]--><div class="stb-column" style="max-width:315px;width:100%!important;margin:0;vertical-align:top;border-collapse:collapse;box-sizing:border-box;font-size:16px;mso-table-lspace:0pt;mso-table-rspace:0pt;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;width:100%;display:inline-block;vertical-align:top;"><!--[if !mso]><!--><div style="padding:15px 15px 0px 15px;"><!--<![endif]--><!--[if mso]> <div > <![endif]--><div style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;"><div data-message-author-role="assistant" data-message-id="5f499d48-bf40-47f4-9ef3-3951cc8d4679" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="2150328f-794d-4628-9524-69c0f5bc1210" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="5e96962a-0360-42f7-8b07-6de2981bd07a" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="0f2a594a-84a2-44c2-89b7-0952819d7c8e" data-message-model-slug="gpt-5"><p data-start="0" data-end="292" data-is-last-node="" data-is-only-node=""><span style="font-size: 14px;">SGLT-2 억제제 ‘자디앙(엠파글리플로진)’의 특허 만료로 24일부터 200여 종 제네릭이 급여 등재와 함께 대거 출시되며 본격 경쟁이 시작됐습니다.</span><br data-start="97" data-end="100"><span style="font-size: 14px;">국내 제약사들은 자디앙 단일제뿐 아니라 DPP-4 억제제와의 2·3제 복합제까지 선보이며 당뇨병 치료제 시장에서 치열한 점유율 경쟁이 예고됩니다.</span><br data-start="181" data-end="184"><span style="font-size: 14px;">업계는 포시가·비아그라 사례처럼 단기적 점유율 하락은 불가피하나, 오리지널 신뢰도와 처방 관행이 초기 시장 우위를 일정 부분 유지할 것으로 전망하고 있습니다.</span></p><p data-start="0" data-end="292" data-is-last-node="" data-is-only-node=""><span style="font-size: 14px;">[약사공론| 25.10.24] </span></p></div></div></div></div></div></div></div><!--[if mso]> </td> <![endif]--><!--[if mso]> <td style='width:50%;padding:15px 15px 0px 15px;' valign='top'> <![endif]--><div class="stb-column" style="max-width:315px;width:100%!important;margin:0;vertical-align:top;border-collapse:collapse;box-sizing:border-box;font-size:16px;mso-table-lspace:0pt;mso-table-rspace:0pt;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;width:100%;display:inline-block;vertical-align:top;"><!--[if !mso]><!--><div style="padding:15px 15px 0px 15px;"><!--<![endif]--><!--[if mso]> <div > <![endif]--><p style="text-align:center;font-size:0;box-sizing:border-box;"><img src="https://img2.stibee.com/440332_3056005_1761278017818491621.png" alt="" style="width:250px;display:inline;vertical-align:bottom;text-align:center;max-width:100% !important;height:auto;border:0;" width="250" class="stb-center"></p></div></div><!--[if mso]> </td> <![endif]--><!--[if mso]> </tr> </table> <![endif]--></div><table role="presentation" class="stb-one-col" style="width: 100%;background:#ffffff;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td class="stb-cta-box" width="100%" style="clear:both;;"><table border="0" cellpadding="0" cellspacing="0" style="width:100%;"><tbody><tr><td style="padding:15px 15px 15px 15px;border:0;width:100%;text-align:center;"><table class="stb-cell-wrap-cta" border="0" cellpadding="0" cellspacing="0" style="color:#000000;mso-padding-alt:0px;border-radius:3px;border:2px solid ;mso-line-height-rule:exactly;box-sizing:border-box;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;display:inline-table;"><tbody><tr><td style="font-size:0;background:none;border-radius:3px;padding:17px 20px;text-align:center;" valign="top"><a href="https://www.brpinsight.com/brand/11233" style="font-size:14px;display:inline-block;color:#000000;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;line-height:1;box-sizing:border-box;mso-line-height-rule:exactly;" target="_blank"><b>BRPInsight 트렌드 - 자디앙과 가장 많이 병용 처방되는 성분 Top 5? [클릭]</b></a></td></tr></tbody></table><table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation"><tbody><tr></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;background:#000000;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;padding:5px 15px 5px 15px;"><h1 class="heading" style="padding: 0px; margin: 0px; line-height: 1.7;"><span class="stb-bold stb-fore-colored" style="font-weight: bold; font-size: 16px; color: #f7f7f7;"><a href="https://www.kpanews.co.kr/article/show.asp?category=D&idx=264294" class="stb-bold stb-fore-colored" style="font-weight: bold; color: #f7f7f7; text-decoration: none;" target="_blank"><span>P-CAB 신약 '들썩' 적응증 확대 제형 다변화 성장세 꾸준</span>🔗</a></span></h1></td></tr></tbody></table><!--[if !mso]><!--><div class="stb-two-col" style="border:0;font-size:0;" name="base2column"><!--<![endif]--><!--[if mso]> <div class='stb-two-col' style='text-align:center;' > <![endif]--><!--[if mso]> <table role='presentation' width='100%' cellpadding='0' cellspacing='0' style='border:0;'> <tr> <![endif]--><!--[if mso]> <td style='width:50%;padding:15px 15px 0px 15px;' valign='top'> <![endif]--><div class="stb-column" style="max-width:315px;width:100%!important;margin:0;vertical-align:top;border-collapse:collapse;box-sizing:border-box;font-size:16px;mso-table-lspace:0pt;mso-table-rspace:0pt;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;width:100%;display:inline-block;vertical-align:top;"><!--[if !mso]><!--><div style="padding:15px 15px 0px 15px;"><!--<![endif]--><!--[if mso]> <div > <![endif]--><div style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;"><div data-message-author-role="assistant" data-message-id="cd67ce81-d697-4c86-af2b-0e6ecb4b034d" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="4e0bc9db-1fcc-4a32-b01f-937ecf68b908" data-message-model-slug="gpt-5"><div><div data-message-author-role="assistant" data-message-id="7a9f1044-5059-42cf-8115-0f5d0134c67e" data-message-model-slug="gpt-5"><p data-start="0" data-end="321" data-is-last-node="" data-is-only-node=""><span style="font-size: 14px;">P-CAB 계열 위식도역류질환 치료제들이 적응증 확대와 신약 진입으로 급성장하며 2024년 처방 시장이 2800억 원 규모로 커졌습니다.</span><br data-start="89" data-end="92"><span style="font-size: 14px;">HK이노엔의 케이캡은 NSAID 유발 궤양 예방 임상 3상에 성공했고, 대원제약의 신약 후보 ‘DW4421’이 임상 3상에 진입했습니다.</span><br data-start="168" data-end="171"><span style="font-size: 14px;">펙수클루는 20mg 제품의 약가 등재를 앞두고 있으며, 자큐보는 1주년 심포지엄을 통해 임상 근거를 강화하며 시장 입지를 넓히고 있습니다.</span></p></div></div><div><div><span style="font-size: 14px;">[약사공론 | 25.10.24]</span></div></div></div></div></div></div></div><!--[if mso]> </td> <![endif]--><!--[if mso]> <td style='width:50%;padding:15px 15px 0px 15px;' valign='top'> <![endif]--><div class="stb-column" style="max-width:315px;width:100%!important;margin:0;vertical-align:top;border-collapse:collapse;box-sizing:border-box;font-size:16px;mso-table-lspace:0pt;mso-table-rspace:0pt;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;width:100%;display:inline-block;vertical-align:top;"><!--[if !mso]><!--><div style="padding:15px 15px 0px 15px;"><!--<![endif]--><!--[if mso]> <div > <![endif]--><p style="text-align:center;font-size:0;box-sizing:border-box;"><img src="https://img2.stibee.com/440332_3056005_1761278163552894130.png" alt="" style="width:285px;display:inline;vertical-align:bottom;text-align:center;max-width:100% !important;height:auto;border:0;" width="285" class="stb-center"></p></div></div><!--[if mso]> </td> <![endif]--><!--[if mso]> </tr> </table> <![endif]--></div><table role="presentation" class="stb-one-col" style="width: 100%;background:#ffffff;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td class="stb-cta-box" width="100%" style="clear:both;;"><table border="0" cellpadding="0" cellspacing="0" style="width:100%;"><tbody><tr><td style="padding:15px 15px 15px 15px;border:0;width:100%;text-align:center;"><table class="stb-cell-wrap-cta" border="0" cellpadding="0" cellspacing="0" style="color:#000000;mso-padding-alt:0px;border-radius:3px;border:2px solid ;mso-line-height-rule:exactly;box-sizing:border-box;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;display:inline-table;"><tbody><tr><td style="font-size:0;background:none;border-radius:3px;padding:17px 20px;text-align:center;" valign="top"><a href="https://www.brpinsight.com/brand/14365" style="font-size:14px;display:inline-block;color:#000000;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;line-height:1;box-sizing:border-box;mso-line-height-rule:exactly;" target="_blank"><b>BRPInsight 트렌드 - P-CAB 계열 약물 내 펙수클의 주별 M/S 추이는? [클릭]</b></a></td></tr></tbody></table><table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation"><tbody><tr></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;background:#000000;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;padding:5px 15px 5px 15px;"><h3 class="heading" style="padding: 0px; margin: 0px; line-height: 1.7;"><span style="font-size: 16px; color: #f7f7f7;" class="stb-fore-colored"><a href="https://www.kpanews.co.kr/article/show.asp?category=C&idx=264309" class="stb-fore-colored" style="color: #f7f7f7; text-decoration: none;" target="_blank"><span style="font-weight: bold;" class="stb-bold"><span>유방암 치료신약 '키스칼리정200mg' RSA 재계약 성공</span>🔗</span></a></span></h3></td></tr></tbody></table><!--[if !mso]><!--><div class="stb-two-col" style="border:0;font-size:0;" name="base2column"><!--<![endif]--><!--[if mso]> <div class='stb-two-col' style='text-align:center;' > <![endif]--><!--[if mso]> <table role='presentation' width='100%' cellpadding='0' cellspacing='0' style='border:0;'> <tr> <![endif]--><!--[if mso]> <td style='width:50%;padding:15px 15px 0px 15px;' valign='top'> <![endif]--><div class="stb-column" style="max-width:315px;width:100%!important;margin:0;vertical-align:top;border-collapse:collapse;box-sizing:border-box;font-size:16px;mso-table-lspace:0pt;mso-table-rspace:0pt;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;width:100%;display:inline-block;vertical-align:top;"><!--[if !mso]><!--><div style="padding:15px 15px 0px 15px;"><!--<![endif]--><!--[if mso]> <div > <![endif]--><div style="word-break:break-all;text-align:left;margin:0px;;line-height:1.7;word-break:break-word;font-size:16px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#000000;"><div data-message-author-role="user" data-message-id="2ca152de-dab1-4cb8-9d8b-dd1b24a4ea52"><div data-multiline=""><div data-message-author-role="user" data-message-id="a934d992-297f-4907-97a5-54d4592afd0d"><div data-multiline=""><div data-message-author-role="assistant" data-message-id="aa208759-725d-4dd0-9f91-c809bb2b666c" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="0a6a0bc8-47e1-4cdf-b637-534904df2836" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="dec45683-20a5-4745-b7e4-22e6b428f5f1" data-message-model-slug="gpt-5"><div><div data-message-author-role="assistant" data-message-id="147fb3bd-4c37-4329-88e0-692e2edaae70" data-message-model-slug="gpt-5"><div data-message-author-role="assistant" data-message-id="51bd4588-6483-425d-97e8-045420260816" data-message-model-slug="gpt-5"><p data-start="0" data-end="187" data-is-last-node="" data-is-only-node=""><span style="font-size: 14px;">노바티스의 유방암 치료제 ‘키스칼리정200mg(리보시클립)’이 건강보험공단과 위험분담계약제(RSA) 재계약을 체결했습니다.</span><br data-start="81" data-end="84"><span style="font-size: 14px;">표시가격은 유지하되 환급형 방식으로 운영돼 제약사가 청구금액의 일부를 공단에 환급하며, 실제 재정 부담은 낮을 전망입니다.</span><br data-start="152" data-end="155"><span style="font-size: 14px;">예상청구액은 약 635억 원 규모로, 건정심 통과 시 내달부터 재계약 조건이 본격 적용될 예정입니다.</span></p></div></div></div><p data-start="0" data-end="211" data-is-last-node="" data-is-only-node=""><span style="font-size: 14px;">[약사공론| 25.10.24] </span></p></div></div></div></div></div></div></div></div></div></div><!--[if mso]> </td> <![endif]--><!--[if mso]> <td style='width:50%;padding:15px 15px 0px 15px;' valign='top'> <![endif]--><div class="stb-column" style="max-width:315px;width:100%!important;margin:0;vertical-align:top;border-collapse:collapse;box-sizing:border-box;font-size:16px;mso-table-lspace:0pt;mso-table-rspace:0pt;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;width:100%;display:inline-block;vertical-align:top;"><!--[if !mso]><!--><div style="padding:15px 15px 0px 15px;"><!--<![endif]--><!--[if mso]> <div > <![endif]--><p style="text-align:center;font-size:0;box-sizing:border-box;"><img src="https://img2.stibee.com/440332_3056005_1761278145660466397.png" alt="" style="width:285px;display:inline;vertical-align:bottom;text-align:center;max-width:100% !important;height:auto;border:0;" width="285" class="stb-center"></p></div></div><!--[if mso]> </td> <![endif]--><!--[if mso]> </tr> </table> <![endif]--></div><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td class="stb-cta-box" width="100%" style="clear:both;;"><table border="0" cellpadding="0" cellspacing="0" style="width:100%;"><tbody><tr><td style="padding:5px 15px 5px 15px;border:0;width:100%;text-align:center;"><table class="stb-cell-wrap-cta" border="0" cellpadding="0" cellspacing="0" style="color:#1b1b1b;mso-padding-alt:0px;border-radius:3px;border:2px solid ;mso-line-height-rule:exactly;width:auto;box-sizing:border-box;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;display:inline-table;"><tbody><tr><td style="font-size:0;background:none;border-radius:3px;padding:17px 20px;text-align:center;" valign="top"><a href="https://www.brpinsight.com/brand/12898" style="font-size:14px;display:inline-block;color:#1b1b1b;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;line-height:1;box-sizing:border-box;mso-line-height-rule:exactly;width:auto;" target="_blank"><b>BRPInsight 트렌드 - 단백질 키나아제 억제제 시장 동향이 궁금하다면? [</b><b>클릭]</b></a></td></tr></tbody></table><table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation"><tbody><tr></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td class="stb-cta-box" width="100%" style="clear:both;;"><table border="0" cellpadding="0" cellspacing="0" style="width:100%;"><tbody><tr><td style="padding:15px 15px 15px 15px;border:0;width:100%;text-align:center;"><table class="stb-cell-wrap-cta" border="0" cellpadding="0" cellspacing="0" style="color:#ffffff;mso-padding-alt:0px;background:#000000;border-radius:500px;mso-line-height-rule:exactly;box-sizing:border-box;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;display:inline-table;"><tbody><tr><td style="font-size:0;background:none;border-radius:500px;padding:17px 20px;text-align:center;" valign="top"><a href="https://www.brpinsight.com/" style="font-size:14px;display:inline-block;color:#ffffff;text-decoration:none;outline:0px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;text-align:center;line-height:1;box-sizing:border-box;mso-line-height-rule:exactly;" target="_blank"><b>25,000여개 제품 트렌드 확인 하러가기 🏃♀️➡️</b></a></td></tr></tbody></table><table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation"><tbody><tr></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;background:#000000;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;background:#000000;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="text-align:justify;font-size:0;box-sizing:border-box;padding:0px 0px 15px 0px;"><img src="https://img2.stibee.com/440332_2904285_1752761435069828722.png" alt="" style="width:100%;display:inline;vertical-align:bottom;text-align:justify;max-width:100% !important;height:auto;border:0;" width="630" class="stb-justify"></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table><table role="presentation" class="stb-one-col" style="width: 100%;border:0;" cellpadding="0" cellspacing="0"><tbody><tr><td style="text-align:center;font-size:0;box-sizing:border-box;padding:15px 15px 15px 15px;"><a href="https://www.brpinsight.com/signup" target="_blank" style="text-decoration: none; color: #0000ff;"><img src="https://img2.stibee.com/440332_3048206_1760946292445398097.png" alt="" style="width:100%;display:inline;vertical-align:bottom;text-align:center;max-width:100% !important;height:auto;border:0;" width="600" class="stb-center"></a></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td class="stb-text-box stb-permalink stb-footer" style="text-align:center;margin:0px;;line-height:1.7;word-break:break-word;font-size:12px;font-family:noto sans kr, noto sans cjk kr, noto sans cjk, Malgun Gothic, apple sd gothic neo, nanum gothic, malgun gothic, dotum, arial, helvetica, Meiryo, MS Gothic, sans-serif!important;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color:#747579;border:0;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="padding:15px 15px 15px 15px;text-align:center;"><div><span>BRPInsight</span><br><span>brpnews@brpinsight.com</span><br><span class="stb-fore-colored">(주)BRP커넥트 | 서울 강남구 역삼로 169 명우빌딩 | </span><br><a href="https://stibee.com/error/preview" class="stb-underline stb-marked" target="_blank" rel="noopener" style="color: #747579;">수신거부</a><span> </span><a href="https://stibee.com/error/preview" class="stb-underline stb-marked" target="_blank" rel="noopener" style="color: #747579;">Unsubscribe</a></div></td></tr></tbody></table></td></tr></tbody></table><table width="100%" cellpadding="0" cellspacing="0" style="border:0;"><tbody><tr><td style="height:15px;" colspan="3"></td></tr><tr><td style="width:15px;"></td><td style="height:15px;background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;"><!-- <div style='background: none;padding: 0px;border-top-width:1px;border-top-style:solid;border-top-color:#999999;margin:0 0;'></div> --></td><td style="width:15px;"></td></tr></tbody></table></div><!--[if mso]> </td> </tr> </table> <![endif]--></td></tr></tbody></table><div style="padding: 10pt 0cm 10pt 0cm;"><p class="MsoNormal" align="center" style="text-align: center;"><span lang="EN-US"></span></p></div></div></body></html>